Vanguard Updates

Photo News

Argatroban injection is about to be grandly launched

Published Time:

2020-06-19

 

In April 2020, Jiangsu Vanguard Pharmaceutical Co., Ltd.'s independently developed argatroban injection obtained a drug registration certificate issued by the National Medical Products Administration and was approved for marketing. The main component of this product is argatroban, used to improve neurological symptoms (motor paralysis) and daily activities (walking, standing, sitting, eating) in acute ischemic stroke patients within 48 hours of onset, and to improve limb ulcers, rest pain, and cold sensitivity in patients with chronic arterial occlusion (thromboangiitis obliterans, obliterative arteriosclerosis).

Previous Page

Vanguard Pharmaceutical organized an emergency drill for environmental emergencies

The company has been awarded the "Gold Medal Enterprise" title for four consecutive years.

Next Page

Previous Page:

Vanguard Pharmaceutical organized an emergency drill for environmental emergencies

Next Page:

The company has been awarded the "Gold Medal Enterprise" title for four consecutive years.

Recommended News

Our company's moxifloxacin hydrochloride eye drops has received an acceptance number from the National Medical Products Administration Center.

2022-05-16

Our company's oseltamivir phosphate for puspension has received the acceptance number from the National Medical Products Administration Center.

2022-05-16

Our company's bromfenac sodium eye drops have received an acceptance number from the National Medical Products Administration Center.

2022-05-16

Vanguard Pharmaceutical organized an emergency drill for environmental emergencies

2021-12-23

Argatroban injection is about to be grandly launched

2020-06-19

The company has been awarded the "Gold Medal Enterprise" title for four consecutive years.

2017-03-06

Warmth delivered to the nursing home, love delivered to Fusan Village

2017-03-06

Jiangsu Vanguard Pharmaceutical Co., Ltd.'s Technology Center has been recognized as a "Jiangsu Provincial Enterprise Technology Research Center"

2016-06-15

Share to

Wangao Pharmaceutical

Return to List
Wangao Pharmaceutical

+86-13776971101

Email: marcos.yuan@wangao.com.cn

Address: No. 688, Dinghai Road, Haimen City, Jiangsu Province

 

Facebook Linkedin Twitter Tumblr Pinterest

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Wangao Pharmaceutical

Mobile Version QR Code

Wangao Pharmaceutical

WeChat Official Account

Copyright © 2025 Jiangsu Wangao Pharmaceutical Co., Ltd.

Powered by www.300.cn丨SEO Tags

Business License